Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer
Article first published online: 6 DEC 1998
Copyright © 1997 Wiley-Liss, Inc.
International Journal of Cancer
Volume 74, Issue 1, pages 50–56, 20 February 1997
How to Cite
Vernon, S. D., Unger, E. R., Miller, D. L., Lee, D. R. and Reeves, W. C. (1997), Association of human papillomavirus type 16 integration in the E2 gene with poor disease-free survival from cervical cancer. Int. J. Cancer, 74: 50–56. doi: 10.1002/(SICI)1097-0215(19970220)74:1<50::AID-IJC9>3.0.CO;2-#
- Issue published online: 6 DEC 1998
- Article first published online: 6 DEC 1998
- Manuscript Revised: 17 SEP 1996
- Manuscript Received: 28 JUN 1996
- American Cancer Society. Grant Number: ACS/IRG 182-C
To determine the clinical relevance of human papillomavirus (HPV) integration and E2 function suggested by in vitro studies, we investigated 50 patients with HPV 16-positive primary cervical carcinoma (stage Ib-IV) diagnosed and treated at one institution. The physical state of HPV was determined by colorimetric in situ hybridization and was not found to vary by stage. Overall, 62% of tumors had integrated HPV, 16% had episomal and 22% had both integrated and episomal. The E1/E2 region was evaluated by 8 separate polymerase chain reactions, which resulted in overlapping products. There was no significant variation in ability to amplify the E1/E2 region with stage. E1/E2 amplification correlated with physical state. Nearly all tumors with episomal or mixed HPV 16 DNA amplified all 8 E1/E2 fragments. Half of the tumors with integrated HPV 16 DNA failed to amplify one or more E1/E2 fragments. Disruptions were most frequent in the E2 region. For all 46 patients receiving curative therapy, the Kaplan-Meier estimate of disease-free survival was determined for those whose primary tumors had amplifiable E2 compared with those lacking one or more E2 DNA fragments. Disruption of E2 was associated with significantly shortened disease-free survival. Int. J. Cancer 74:50–56. © 1997 Wiley-Liss, Inc.